BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia

CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells

(2014) Yang Cao et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

(2014) S E M Herman et al.   LEUKEMIA

PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1)

(2014) S. Decker et al.   MOLECULAR CANCER THERAPEUTICS

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

(2014) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

(2014) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

(2013) Rakesh Bam et al.   AMERICAN JOURNAL OF HEMATOLOGY

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

Endocytic trafficking of chemokine receptors

(2013) Adriano Marchese   CURRENT OPINION IN CELL BIOLOGY

Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells

(2013) Jingming Wang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CXCR4-SERINE339 regulates cellular adhesion, retention and mobilization and is a marker for poor prognosis in acute myeloid leukemia

(2013) L Brault et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling

(2013) S.-S. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials

(2013) Jennifer R. Brown   Current Hematologic Malignancy Reports

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

Protein Kinase D Signaling: Multiple Biological Functions in Health and Disease

(2011) Enrique Rozengurt   PHYSIOLOGY

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

(2010) C. C. Chu et al.   BLOOD

Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling

(2010) John M. Busillo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL

(2010) Aneela Majid et al.   LEUKEMIA RESEARCH

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia

(2009) C. Calissano et al.   BLOOD

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA

(2008) C. C. Chu et al.   BLOOD